biomedicines

IMPACT FACTOR 4.7

Indexed in: PubMed

CITESCORE 3.7

an Open Access Journal by MDPI

Malignant Pleural Mesothelioma: From Pathophysiology to Novel Therapeutic Approaches

Guest Editor:

Dr. Yanyun Gao
University Hospital Bern, Bern, Switzerland

Deadline for manuscript submissions:
31 October 2024

Message from the Guest Editor

Dear Colleagues,

Mesothelioma is a rare, but aggressive cancer type, originating from mesothelium tissues covering the lungs (pleura), heart (pericardium), abdomen (peritoneum) and testes (tunicae testis). However, 90% of mesothelioma cases are of malignant pleural mesothelioma (MPM), which is usually associated with exposure to asbestos. MPM involves tumour suppressor gene mutation instead of oncogenes, so targeted therapies are rarely applied. In the last two decades, chemotherapy has been the only fist-line treatment for unresectable MPM. Immunotherapy was approved by FDA in 2020, but only a small population of patients benefit from it. Further studies are needed to understand this disease and develop novel therapeutic approaches. In this collection, we aim to include research focused on the histological, molecular, and biological mechanisms of MPM and pleural effusion, the potential biomarkers for different treatment strategies, advanced diagnostic techniques, novel therapies for MPM (targeted, metabolomic, and immune therapies), and promising models of MPM (organoids, tissue slices, and mouse models).

Dr. Yanyun Gao
Guest Editor

biomedicines

IMPACT FACTOR 4.7 | Indexed in: PubMed | CITESCORE 3.7

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
𝕏@Biomed_MDPI